참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | Methanesulfonic Acid | HCID 6395 | — |
| 반응물 | Eprosartan | HCID 5281037 | — |
| 용매 | Acetic Acid | HCID 176 | — |
| 생성물 | Eprosartan Mesylate | HCID 5282474 | — |
반응 단계
After numerous trials, the inventor found that: eprosartan was suspended or dissolved in glacial acetic acid, then methanesulfonic acid was added to obtain a clear solution of eprosartan mesylate in glacial acetic acid; after about 1 hour of stirring, eprosartan mesylate solid would precipitate slowly, and thus the salification of eprosartan with methanesulfonic acid avoids embedment; ethyl acetate was added to render eprosartan mesylate crystallized completely, the obtained solid was easy to filter and drain under a reduced pressure, the wet product obtained had a low solvent content and thus was easy to dry. In addition, the new process of adding methanesulfonic acid into a solution of eprosartan in acetic acid did not produce new impurities, and the originally existing impurities decreased by some extent.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 특허 번호 | US08546585B2 |
|---|
| 출처 데이터셋 | uspto-grants-2013_10 |
|---|
| ORD ID | ord-5c5c24b4904c4c7ba778109f48b42b22 |
|---|
| 출처 메모 | uspto-grants-2013_10 |
|---|